IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment
NCT04915326 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 466
Last updated 2021-06-07
Summary
ABSTRACT Background The current management on rectal cancer based on TNM staging has some limitations. In early rectal cancer T stage can be not sufficient to predict the nodal status and, in locally advanced rectal cancer after neoadjuvant therapy the persistence of a complete response to therapy cannot be accurately predicted by the simple tumor regression grade. For both cases the current guidelines recommend the complete rectal resection with a total mesorectal excision. The implications for patients' quality of life are evident even in case of sphincter sparing surgery. Moreover, in both cases the cancer sample available for the analysis can be small or inexistent.
Hypothesis The main hypothesis underlying our research is that the aggressiveness of rectal cancer is determined by the complex interactions between the malignant cells and their immune microenvironment. The second hypothesis is that relevant trace of this cross talk between tumor cells and immune microenvironment can be detected in the normal mucosa surrounding the cancer according to the concept of field cancerization.
Aims The aim of this project is to analyze the healthy rectal mucosa surrounding the cancer to identify traces of immunosurveillance mechanisms and of field cancerization and to use them to obtain a composite prognostic test to predict nodal metastasis in early rectal cancer and recurrence after complete response at neoadjuvant therapy in case of locally advanced rectal cancer.
Experimental Design This prognostic test will be constructed on the combinatory analysis of the transcriptome, immune and epithelial cells cross-talk, immune checkpoints and miRNA expression in normal rectal mucosa surrounding cancer. The aim is to predict the presence of nodal metastasis in patients with early rectal cancer. In step A, we will retrospectively analyze archival tissue samples in order to identify the most performing biomarkers; in step B, we will validate the prognostic performance of the markers identified in phase I through a prospective analysis of rectal mucosa specimen.
Expected Results The anticipated outcome of this project is to generate one or different combination of markers to optimize rectal management and to predict rectal cancer patients outcome more accurately than traditional TNM staging or tumore regression grade. We expect to obtain a prognostic test from normal tissue that accurately predicts rectal cancer behavior even in case when the tumor samples are scarce (early rectal cancer) or absent (complete response to therapy) to avoid unnecessary total rectal excision.
Impact On Cancer An immunoscore specific for rectal cancer may predict tumor progression and clinical outcome more accurately and may contribute to better design a personalized therapeutic algorithm. Moreover, nowadays patients with early rectal cancer without nodal involvement and patients with potential complete response to neoadjuvant therapy still undergo total rectal excision which is a risky procedure that impairs quality of life. The use of this new prognostic test may make possible to adopt a minimally invasive approach or even simple observation if nodal involvement or residual disease are reasonably excluded.
Conditions
- Rectal Cancer Stage T1-T2
- Rectal Cancer Nodal Metastasis
Interventions
- PROCEDURE
-
rectal resection
every patients will undergo to the appropriate rectal resection
Sponsors & Collaborators
-
Associazione Italiana per la Ricerca sul Cancro
collaborator OTHER -
Istituto Oncologico Veneto IRCCS
collaborator OTHER -
Azienda ULSS 3 Serenissima
collaborator OTHER -
Azienda Ulss 2 Marca Trevigiana
collaborator OTHER -
University of Padova
lead OTHER
Principal Investigators
-
Marco Scarpa, MD, PhD · Clinica Chirurgica I, Azienda Ospedale Università di Padova
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-01-01
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
Countries
- Italy
Study Locations
More Related Trials
-
Immunotherapy In Locally Advanced Rectal Cancer
NCT03854799 ·Status: COMPLETED ·Phase: PHASE2
-
Preoperative Chemo-radiation With IG-IMRT Dose Escalation for Locally Advanced Rectal Cancers
NCT03200249 ·Status: COMPLETED ·Phase: NA
-
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
NCT05479240 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors
NCT03177382 ·Status: UNKNOWN ·Phase: PHASE3
-
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
NCT07214142 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Ultrasound Elastography in Patients With Rectal Cancer
NCT01379612 ·Status: COMPLETED
-
Phase I/II Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Recurrent Rectal Cancer
NCT01528683 ·Status: COMPLETED ·Phase: NA
-
Mesorectal Microbiome as a Prognostic Factor in Patients With Rectal Cancer
NCT04804956 ·Status: RECRUITING
-
A Prospective Phase II Randomized Clinical Trial of Preoperative Chemotherapy Combined With Short-course Radiotherapy Versus Conventional Neo-adjuvant Therapy for Locally Advanced Rectal Cancer Implemented by MDT
NCT02941562 ·Status: UNKNOWN ·Phase: PHASE2
-
AIMS Academy Clinical Research Network - Non Metastatic Rectal Cancer Operated on With Curative Intent
NCT04045236 ·Status: WITHDRAWN
-
Resource-Sparing Curative Treatment for Rectal Cancer
NCT01459328 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of cfDNA as a Marker of Response in Rectal Cancer
NCT04319354 ·Status: COMPLETED ·Phase: NA
-
A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.
NCT01941979 ·Status: UNKNOWN ·Phase: PHASE3
-
Microbiome and Rectal Cancer
NCT04223102 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Chemo-radiotherapy as Main Treatment Strategy for Rectal Cancer. Can we Provide a More Precise and Effective Treatment
NCT03619668 ·Status: UNKNOWN
-
ctDNA-Informed Management of Early-Stage Rectal Cancer
NCT07209215 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis
NCT05359406 ·Status: UNKNOWN ·Phase: PHASE2
-
Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis
NCT01923987 ·Status: UNKNOWN ·Phase: PHASE2
-
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
NCT04664504 ·Status: RECRUITING ·Phase: PHASE2
-
Oncological Impact of Lateral Nodes in Rectal Cancer
NCT05592873 ·Status: COMPLETED
-
Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer
NCT06293612 ·Status: COMPLETED
-
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
NCT05495308 ·Status: COMPLETED
-
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
NCT07113275 ·Status: RECRUITING ·Phase: PHASE3
-
Study of the Predictive and Prognostic Role of Pharmacogenetic and Radiogenic Variants on the Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer
NCT06616870 ·Status: NOT_YET_RECRUITING
-
Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
NCT07161115 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2